Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

Shengyu Zhang, Lei Li, Aizong Shen, Yongwu Chen, Zhigang Qi, Shengyu Zhang, Lei Li, Aizong Shen, Yongwu Chen, Zhigang Qi

Abstract

Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that ⁓ 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and "Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)" in China, so as to provide reference for the treatment of COVID-19.

Conflict of interest statement

Shengyu Zhang, Lei Li, Aizong Shen, Yongwu Chen and Zhigang Qi declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
The potential mechanism of tocilizumab in the treatment of cytokine storm induced by COVID-19 SARS-CoV-2 severe acute respiratory syndrome coronavirus 2; IL interleukin, MAPK mitogen-activated protein kinase

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. 2019;2020:2020. doi: 10.1101/2020.02.06.20020974.
    1. Xu KJ,Cai HL,Shen YH,et a1. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao (Yi Xue Ban). 2020. . Accessed 3 Mar 2020 (in Chinese).
    1. General Office of the National Health Committee of China, China Traditional Chinese Medicine Administration Office. Diagnosis and treatment plan of novel coronavirus pneumonia (seventh trial edition). 2020. . Accessed 11 Mar 2020.
    1. Jennifer RT, Marcus JK, Cameron PS, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.
    1. Fei ZY, Dong H, Qian QJ, et al. Analysis of pathogens and risk factors for death in elderly patients with severe pneumonia. Zhong Hua Yi Yuan Gan Ran Xue Za Zhi. 2019;29(3):380–383.
    1. Ma YP, Yan YH, Sun XD, et al. Correlation between inflammatory factor expression level in severe pneumococcal alveolar lavage fluid and prognosis. Zhong Hua Yi Yuan Gan Ran Xue Za Zhi. 2019;29(7):1007–1010.
    1. Zhang JW, Hu X, Jin PF. Cytokine storm induced by SARS-CoV-2 and the drug therapy. Zhongguo Yao Xue Za Zhi. 2020. . Accessed 9 Feb 2020 (in Chinese).
    1. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc. 1993;25(1 Pt 2):1216–17.
    1. De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–1207.
    1. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–679.
    1. Zhang YL, Jiang CY. Cytokine storm in ARDS. Sheng Ming Ke Xue. 2015;5:554–557.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475.
    1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2019;2020:2020. doi: 10.1001/jama.2020.1585.
    1. Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
    1. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhong Hua Jie He He Hu Xi Za Zhi. 2019;2020:2020. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
    1. Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) MedRxiv. 2019;2020:2020. doi: 10.1101/2020.02.10.20021832.
    1. Jing L, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. MedRxiv. 2020 doi: 10.1101/2020.02.16.20023671.
    1. Zhai H, Liu YW, Wang Y, et al. The pathogen distribution and its influence on inflammatory factors in old patients with heart failure complicated with pulmonary infection. Tianjin Yi Yao. 2018;46(9):952–955.
    1. Zhou YG, Fu BQ, Zheng XH, et al. Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv. 2020 doi: 10.1101/2020.02.12.945576.
    1. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–970.
    1. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–e131.
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
    1. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789.
    1. Braun GS, Nagayama Y, Maruta Y, et al. IL-6 trans-signaling drives murine crescentic GN. Am Soc Nephrol. 2016;27(1):132–142.
    1. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
    1. Zegeye MM, Madelene L, Knut F, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018;16(1):55.
    1. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248.
    1. Rose-John S. The soluble Interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Ther. 2017;102(4):591–598.
    1. The first affiliated hospital of university of science and technology. The efficacy and safety of tocilizumab in the treatment of novel coronavirus pneumonia: a multi-center, randomized, double-blinded trial. 2020. . Accessed 22 Feb 2020.
    1. Genentech. Genentech announces FDA approval of clinical trial for actemra to treat hospitalized patients with severe COVID-19 Pneumonia;. 2020. . Accessed 27 Mar 2020.
    1. Xu XL, Han MF, Li TT, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv. 2020. . Accessed 20 Mar 2020.
    1. The U.S. Food and Drug Administration. Information for ACTEMRA® (tocilizumab). . Accessed 15 Feb 2020.
    1. Ferfar Y, Mirault T, Desbois AC, et al. Biotherapies in large vessel vasculitis. Autoimmun Rev. 2016;15(6):544–551.
    1. Samson M, Devilliers H, Ly KH, et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: a prospective study. Eur J Intern Med. 2018;57:96–104.
    1. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan(the TAKT study) Ann Rheum Dis. 2018;77(3):348–354.
    1. Liao H, Pan LL, Du J, et al. Efficacy and safety of tocilizumab in patients with Takayasu arteritis. Zhong Hua Nei Ke Za Zhi. 2019;58(6):444–448.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever